地西他滨对骨髓增生异常综合征患者的临床疗效与安全性评价

Evaluation on Clinical Efficacy and Safety of Decitabine in Patients with Myelodysplastic Syndrome

目的:评价地西他滨对骨髓增生异常综合征患者的临床疗效。方法:选取2014年1月—2017年12月期间收治的骨髓增生异常综合征患者60例资料,采用随机数字表法将其分为参照组和观察组,每组30例;观察组患者给予地西他滨治疗,参照组患者给予联合化疗(三尖杉酯碱、阿糖胞苷或柔红霉素、阿糖胞苷)治疗;比较两组患者治疗后的总有效率、用药期间不良反应发生率差异,以及治疗后生活质量评分值的变化情况。结果:治疗后观察组患者的总有效率为70.00%高于参照组为60.00%,经两组间比较其差异无统计学意义(P>0.05);用药期间观察组患者不良反应的发生率为10.00%明显低于参照组为60.00%(P<0.05),生活质量各指标评分值均明显高于参照组(P<0.05)。结论:对于骨髓增生异常综合征患者,采用地西他滨或者联合化疗方案治疗的临疗效果基本相当,但地西他滨用药期间安全性较高,有效改善了其生活质量。

Objective： To evaluate the clinical efficacy and safety of decitabine in patients with myelodysplastic syndrome. Methods： The data of 20 patients with myelodysplastic syndrome who were admitted to our hospital from January 2014 to December 2017 were selected as the subjects of this study. Using to the random number table method, they were divided into two groups, each accounting for 30 cases. One group of patients were treated with decitabine and the other group were treated with combination chemotherapy （harringlonine, cytarabinc or daunorubicin,cytarabine）. The total treatment efficacy, incidence of adverse reactions and changes in quality of life were compared between the two groups of patients. Results： After treatment, the total effective rate was 70.00% in the experimental group and 60.00% in the comparison group. There was no significant difference in the total effective rate between the two groups （P〉0.05）; the incidence of adverse reactions in the experimental group was 10.00%, significantly lower than those of the control group （60.00%）, the difference was statistically significant （P〈0.05）; the quality of life indicators in the ex- perimental group were significantly higher than that of the comparison group; the difference was statistically significant （P〈0.05）. Conclusion： For patients with myelodysplastic syndrome, the therapeutic effect of dixitabine or combined chemotherapy is basically the same, but the safety of dixitabine is higher and the quality of life is effectively improved.